Trial Profile
Reversal of deep pipecuronium neuromuscular block using sugammadex: a randomized, double-blind, dosefinding study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2018
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 29 Aug 2018 Primary endpoint (The time to achieve the normalized TOF ratio of 0.9 in a particular patient.) has been met, according to results published in the Anesthesia and Analgesia.
- 29 Aug 2018 Results published in the Anesthesia and Analgesia
- 29 Aug 2018 Status changed from recruiting to completed, according to results published in the Anesthesia and Analgesia.